⚠ Evidence warning: Clinical trials or other evidence do not support the claim that chanca piedra helps a kidney stone pass at home and relaxes the ureter (the one placebo-controlled trial found no difference in stone passage or pain relief, the lithotripsy study found a significant benefit only for stones in the lower part of the kidney, and no trial has measured ureter relaxation). This page keeps it as a report of what people, websites or other media say.

Chanca Piedra Kidney-Stone Protocol

Kidney Stone Protocol — scientific infographic poster

The Spanish name chanca piedra means “stone breaker” (in Brazil the plant is called quebra-pedra, Portuguese for the same thing), and the Spanish-speaking Amazon has used Phyllanthus niruri for urolithiasis for at least four centuries. This page describes the step-by-step home protocol that practitioners and patients use: who it is described for, how the herb is combined with hydration and pH management, the timelines reported, how it fits with conventional urology (lithotripsy, ureteroscopy, nephrology follow-up), and the warning signs that hospitals treat as emergencies. The companion Kidney Stones Benefits page reviews the underlying clinical-trial evidence; this page describes the practice. It does not replace a urologist’s assessment of a specific stone — it lays out the structured framework the practice follows.

Table of Contents

  1. Overview — What the Protocol Is and Who It Is Described For
  2. Stone Types and Mechanism of Action
  3. Pre-Protocol Assessment
  4. Daily Protocol — Step by Step (Acute Phase)
  5. Maintenance Phase — Recurrence Prevention
  6. Combining with Conventional Care
  7. Expected Timeline and Signs of Progress
  8. Drug Interactions and Cautions During Protocol
  9. Red Flags — Signs Hospitals Treat as Emergencies
  10. Key Research Papers
  11. Connections
  12. Featured Videos

Overview — What the Protocol Is and Who It Is Described For

As practitioners describe it, this protocol is a structured 2- to 4-week home regimen intended to (a) reduce crystal aggregation in the renal pelvis and ureter, (b) relax ureteral smooth muscle to ease stone passage, and (c) increase urine flow rate so existing stones move and new ones don’t form. It is built around standardized Phyllanthus niruri extract, aggressive but controlled hydration, dietary pH management, and ureteric symptom tracking. It is not a stand-alone cure: it is the patient-facing scaffolding around a urology workup.

Who practitioners describe the protocol for:

Who practitioners exclude from the protocol:

Practitioners present the protocol as a structured way to give an in-the-window stone a fair chance to pass spontaneously alongside contact with a urology team, not as a substitute for imaging or for clinical follow-up.

Back to Table of Contents

Stone Types and Mechanism of Action

Kidney stones are not a single disease. Composition drives everything: dietary changes, urinary pH targets, the antibiotic question, and the herb’s likely usefulness. The major types in adults:

How Chanca Piedra is proposed to work against calcium-oxalate stones — what the studies found:

  1. Smaller, less clumped crystals (in a dish). When Barros and colleagues (2003) added an aqueous P. niruri extract to urine samples from healthy people and from rats and then triggered calcium oxalate crystal formation, the extract did not stop crystals forming — even more crystals appeared — but they were significantly smaller, and crystal clumping (aggregation) 24 hours later was reduced. The authors suggested the herb may interfere with the early stages of stone formation. This was a test-tube result, not urine from people taking the herb.
  2. Slower stone growth, with glycosaminoglycans moving into the stones (rats). In a 42-day rat study (Freitas 2002), P. niruri strongly slowed the growth of a bladder stone seeded with calcium oxalate and reduced the number of satellite stones; the stones were eliminated or dissolved in 3 of 22 treated rats. Urinary glycosaminoglycans (GAGs, natural inhibitors of crystallization) were lower in the treated rats (5.64 vs 11.78 mg per gram of creatinine), while the GAG content of the stones was higher (48.0 vs 16.6), so the authors linked the effect to more GAGs being built into the stones rather than to more GAGs in the urine. Urinary citrate and magnesium did not change. In a separate cell study, the extract strongly reduced the uptake of calcium oxalate crystals by dog kidney tubular cells grown in a dish (Campos 1999).
  3. Smooth-muscle relaxation of the ureter. Practitioners attribute to the herb’s lignans (phyllanthin, hypophyllanthin) and ellagitannins (geraniin, corilagin) a mild calcium-channel-blocker-like effect on ureteral smooth muscle, reducing the spasm component of renal colic and easing transit; a 2010 review by the Brazilian research group also named ureteral relaxation as one possible explanation for the herb’s clinical effects (Boim 2010). Patients on Chanca Piedra report a less crampy passage experience.
  4. Mild diuresis. Practitioners describe an increase in urine output by a measurable but modest amount, helping clear small stones and fragments. The diuresis is not driven by potent salt-wasting; it is a soft, sustained effect.
  5. Geraniin to urolithins. The ellagitannin geraniin is metabolized by gut microbiota into urolithins, which are proposed to provide systemic anti-inflammatory cover during the irritation phase of stone passage. This is the same urolithin pathway active for pomegranate ellagitannins.
  6. Lower urinary calcium in people with high urinary calcium. In a placebo-controlled trial (Nishiura 2004), 69 calcium stone formers took P. niruri 450 mg capsules three times daily or placebo for 3 months. Overall, 24-hour urine chemistry did not change, apart from a slight fall in urinary magnesium that stayed within the normal range; in the subgroup with high urinary calcium (hypercalciuria), urinary calcium fell from 4.8 to 3.4 mg/kg per 24 hours. Over this short follow-up there were no significant differences in stone passage or pain relief between the herb and placebo groups.

For uric-acid stones, the dominant intervention is urinary alkalinization with potassium citrate — Chanca Piedra is at best secondary. For struvite, the dominant intervention is antibiotic eradication of the urea-splitting infection plus mechanical stone clearance — Chanca Piedra is not described as having a role.

Back to Table of Contents

Pre-Protocol Assessment

Practitioners describe a minimum workup before the herb is used for a current episode:

Imaging confirmation:

What the imaging shows that bears on the protocol:

Labs to baseline:

Hard contraindications — situations in which practitioners do not use herb-assisted passage:

Back to Table of Contents

Daily Protocol — Step by Step (Acute Phase)

The acute phase runs for 2–4 weeks from the start of symptoms or from a recent procedure. The goal is spontaneous passage of the index stone (or post-procedure fragments) while supporting symptom control.

Hydration

Hydration is described as the single most important variable. The usual target is at least 2.5 to 3.5 liters of urine output per 24 hours, which usually takes 3–4 liters of fluid intake spread evenly across waking hours plus 250–500 mL on waking after a night of getting up.

Urine output and color. Urine color tracks hydration loosely: pale straw is the target, dark amber means fluid intake is behind, clear-and-frequent is fine. Passing urine less often than every 2–3 hours during the day is a sign of too little fluid.

Chanca Piedra dosing — acute phase

What is in the bag. DNA testing of herbal teas sold in Brazil as quebra-pedra (Inglis 2018) found that the packaged dried herb from three suppliers was a different species, Phyllanthus tenellus, one of them also mixed with alfalfa, and that a fourth supplier’s product was a mixture of Desmodium barbatum and P. niruri. The authors note that of the four Phyllanthus species used for kidney stones in Brazilian folk medicine, only P. niruri has been shown to be effective in a clinical setting.

The Forms, Dosing and Standardization page covers the full dosing matrix, product notes, and shelf-life considerations.

Timing: practitioners describe taking it with meals; the meal-protein context helps stabilize gastric tolerance and the lignans absorb well in a mixed-meal matrix. Black or green tea within an hour is described as reducing absorption (tannins compete).

Urine pH targeting

pH matters more than people realize. Practitioners describe pH test strips (range 4.5 to 8.0) used on first-morning urine and one mid-afternoon void daily for the first week.

Gentle alkalinization for CaOx or uric-acid stones comes from lemon juice (above), potassium-rich plant foods and alkaline mineral waters. For a stronger effect, urology often prescribes potassium citrate 10–20 mEq three times daily; high-dose oral alkali affects blood potassium and the body’s acid-base balance, which is why it is given on prescription and checked with blood tests.

Diet during acute passage

Urine straining

Practitioners describe straining every void during acute passage, with a stone-collection strainer from a pharmacy or a coffee filter over a clean container. Once a stone is caught, the usual steps are:

Symptom control

Back to Table of Contents

Maintenance Phase — Recurrence Prevention

About half of all first-time stone formers will form another stone within 5–10 years if no preventive measures are adopted. The maintenance phase is where practitioners place most of Chanca Piedra’s use, based on the anti-aggregation findings above.

Maintenance dosing described by practitioners — structured cycling:

Lifestyle priorities for sustained prevention:

Follow-up imaging — renal ultrasound annually is common for high-recurrence patients; non-contrast computed tomography is reserved for symptomatic episodes or unusual presentations to limit radiation exposure.

Back to Table of Contents

Combining with Conventional Care

Herbal-assisted passage and modern urology are not opposites. The clearest positive result in the published studies came from using the herb alongside lithotripsy.

As an adjunct to extracorporeal shock-wave lithotripsy (ESWL)

This is the best-studied indication. In the randomized study of P. niruri after lithotripsy (Micali 2006), 150 patients with calcium oxalate kidney stones up to 25 mm had 1 to 3 ESWL sessions; 78 then took a P. niruri extract (2 g daily) for at least 3 months and 72 served as controls. At 180 days the stone-free rate (no stone, or fragments under 3 mm) was 93.5% with the herb and 83.3% without, a difference that was not statistically significant (p = 0.48); for stones in the lower part of the kidney (lower calyx, 56 patients) it was 93.7% versus 70.8% (p = 0.01). Re-treatment was needed in 39.7% versus 43.3%, and no side effects were recorded. Pucci and colleagues (2018) studied a different question, without a placebo group: in 56 patients with kidney stones under 10 mm who drank P. niruri infusion (tea) for 12 weeks, urinary potassium and the magnesium-to-creatinine ratio rose, urinary oxalate fell from 59.0 to 28.8 mg per 24 hours in those with high urinary oxalate, urinary uric acid fell in those with high urinary uric acid, and the number of stones per patient fell from 3.2 to 2.0. The proposed mechanism for the lithotripsy result is the combination of anti-aggregation (preventing fragment re-cohesion) plus mild diuresis (washing fragments through the ureter) plus ureteral smooth-muscle relaxation (easing transit through the ureterovesical junction).

In practice, the question comes up for people in the “fragment clearance” phase after ESWL on a renal-pelvis or upper-ureteral stone. The lithotripsy study used 2 g of extract daily for at least 3 months, not the 400 mg three times daily for 4–8 weeks often described in practice. Many urologists are open to the herb for adherent, motivated patients; some are skeptical of the evidence.

What reviews of the evidence conclude

A 2020 meta-analysis (Dhawan and Olweny) found only two controlled human studies reporting stone size and number. Pooled, P. niruri reduced mean stone size (standardized mean difference −0.39) and stone number (−0.38), and the authors concluded that limited clinical evidence supports modest efficacy, pending further study. A 2025 systematic review of 16 human and rat studies (Iregui-Parra and colleagues) reported that serial measurements of blood electrolytes and liver function consistently supported the herb’s long-term safety, and that as an add-on after shock-wave lithotripsy it showed benefit for stones in the lower pole of the kidney.

As an adjunct to ureteroscopy (URS)

Less studied than ESWL adjunct. Practitioners consider it plausibly useful for the same reasons (residual fragment clearance, ureteral relaxation around the stent), but the evidence base is thinner. A double-J (JJ) ureteral stent left in place after URS commonly causes bladder irritation; the herb is not described as easing stent pain, while anticholinergics or alpha-blockers are used for it.

Medical expulsive therapy (MET) overlap

Tamsulosin is widely prescribed for ureteral stones in the 5–10 mm range. Chanca Piedra is mechanistically additive, not redundant: tamsulosin is an alpha-1 antagonist (ureteral and lower-urinary-tract effect), Chanca Piedra works partly through general smooth-muscle relaxation. There is no published interaction between the two; clinicians and patients combining them have not reported a problem.

Situations that involve nephrology and urology

Back to Table of Contents

Expected Timeline and Signs of Progress

Realistic expectations matter. Stone-passage timing depends mostly on stone size and location at the moment the protocol begins.

Signs of progress (good news):

Signs of no progress (decision point):

Hematuria interpretation: mild discoloration of urine for several days during acute passage is normal. Frank red blood, large clots, or hematuria that persists more than 7–10 days after the stone has clearly passed is a finding urologists investigate.

Back to Table of Contents

Drug Interactions and Cautions During Protocol

A condensed version is here; the full list lives on the Safety, Drug Interactions and Cautions page.

Pregnancy: not established as safe; there is no good safety data in pregnancy.

Breastfeeding: insufficient data; standard guidance advises against use while breastfeeding.

Pre-operative discontinuation: the usual practice is stopping Chanca Piedra at least 2 weeks before any planned surgery (cytochrome P450 3A4 and antiplatelet considerations).

Back to Table of Contents

Red Flags — Signs Hospitals Treat as Emergencies

The following are signs that hospitals treat as emergencies, or as needing urgent evaluation, during stone passage; practitioners stop the protocol when any of them appears:

Three sentinel symptoms deserve special emphasis because patients dismiss them too readily:

  1. Fever plus stone symptoms is an emergency. Not a “wait and see” situation. Infected obstruction can progress to urosepsis in hours.
  2. Not urinating is an emergency. Not normal at any point in the protocol.
  3. Pain that breaks through full-dose nonsteroidal anti-inflammatory drug plus tamsulosin plus the herb is an indication that the protocol is failing. Either the stone has not moved or it is causing damage; this is the point for re-imaging.

The protocol exists to give an in-the-window stone a fair chance to pass at home. It does not exist to replace urgent or emergent urologic care.

Back to Table of Contents

Key Research Papers

  1. Barros ME, Schor N, Boim MA. Effects of an aqueous extract from Phyllanthus niruri on calcium oxalate crystallization in vitro. Urol Res 2003;30(6):374-9. — PubMed PMID: 12599017 · doi:10.1007/s00240-002-0285-y
  2. Nishiura JL, Campos AH, Boim MA, Heilberg IP, Schor N. Phyllanthus niruri normalizes elevated urinary calcium levels in calcium stone forming (CSF) patients. Urol Res 2004;32(5):362-6. — PubMed PMID: 15221244 · doi:10.1007/s00240-004-0432-8
  3. Micali S, Sighinolfi MC, Celia A, et al. Can Phyllanthus niruri affect the efficacy of extracorporeal shock wave lithotripsy for renal stones? A randomized, prospective, long-term study. J Urol 2006;176(3):1020-2. — PubMed PMID: 16890682 · doi:10.1016/j.juro.2006.04.010
  4. Pucci ND, Marchini GS, Mazzucchi E, et al. Effect of Phyllanthus niruri on metabolic parameters of patients with kidney stone: a perspective for disease prevention. Int Braz J Urol 2018;44(4):758-764. — PubMed PMID: 29617079 · doi:10.1590/S1677-5538.IBJU.2017.0521
  5. Freitas AM, Schor N, Boim MA. The effect of Phyllanthus niruri on urinary inhibitors of calcium oxalate crystallization and other factors associated with renal stone formation. BJU Int 2002;89(9):829-34. — PubMed PMID: 12010223 · doi:10.1046/j.1464-410x.2002.02794.x
  6. Campos AH, Schor N. Phyllanthus niruri inhibits calcium oxalate endocytosis by renal tubular cells: its role in urolithiasis. Nephron 1999;81(4):393-7. — PubMed PMID: 10095174 · doi:10.1159/000045322
  7. Boim MA, Heilberg IP, Schor N. Phyllanthus niruri as a promising alternative treatment for nephrolithiasis. Int Braz J Urol 2010;36(6):657-64; discussion 664. — PubMed PMID: 21176271 · doi:10.1590/s1677-55382010000600002
  8. Calixto JB, Santos AR, Cechinel Filho V, Yunes RA. A review of the plants of the genus Phyllanthus: their chemistry, pharmacology, and therapeutic potential. Med Res Rev 1998;18(4):225-58. — PubMed PMID: 9664291 · doi:10.1002/(sici)1098-1128(199807)18:4<225::aid-med2>3.0.co;2-x
  9. Patel JR, Tripathi P, Sharma V, Chauhan NS, Dixit VK. Phyllanthus amarus: ethnomedicinal uses, phytochemistry and pharmacology: a review. J Ethnopharmacol 2011;138(2):286-313. — PubMed PMID: 21982793 · doi:10.1016/j.jep.2011.09.040
  10. Devarbhavi H, Aithal G, Treeprasertsuk S, et al. Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. Hepatol Int 2021;15(2):258-282. — PubMed PMID: 33641080 · doi:10.1007/s12072-021-10144-3
  11. Curhan GC, Willett WC, Speizer FE, Spiegelman D, Stampfer MJ. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 1997;126(7):497-504. — PubMed PMID: 9092314 · doi:10.7326/0003-4819-126-7-199704010-00001
  12. Borghi L, Schianchi T, Meschi T, et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 2002;346(2):77-84. — PubMed PMID: 11784873 · doi:10.1056/NEJMoa010369
  13. Dhawan S, Olweny EO. Phyllanthus niruri (stone breaker) herbal therapy for kidney stones; a systematic review and meta-analysis of clinical efficacy, and Google Trends analysis of public interest. Can J Urol 2020;27(2):10162-10166. — PubMed PMID: 32333735
  14. Iregui-Parra J, Rojas Ossa V, Arias Salazar CM, et al. Phyllanthus niruri in the management of nephrolithiasis: A systematic review of the literature. Actas Urol Esp (Engl Ed) 2025;49(6):501791. — PubMed PMID: 40480426 · doi:10.1016/j.acuroe.2025.501791
  15. Inglis PW, Mata LR, da Silva MJ, et al. DNA Barcoding for the Identification of Phyllanthus Taxa Used Medicinally in Brazil. Planta Med 2018;84(17):1300-1310. — PubMed PMID: 29929208 · doi:10.1055/a-0644-2688

PubMed Topic Searches

  1. PubMed: P. niruri kidney stone
  2. PubMed: P. niruri calcium oxalate
  3. PubMed: Phyllanthus + ESWL
  4. PubMed: Phyllanthus + hypercalciuria
  5. PubMed: medical expulsive therapy
  6. PubMed: stone recurrence prevention
  7. PubMed: potassium citrate & urolithiasis
  8. PubMed: uric-acid stone dissolution

Back to Table of Contents

Connections

Back to Table of Contents